|
Dec 30
|
FDA approves BMS’ Opdivo Qvantig for solid tumour indications
|
|
Dec 29
|
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
|
|
Oct 11
|
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Oct 11
|
Top Research Reports for Bristol-Myers, Arthur J. Gallagher & TC Energy
|
|
Oct 9
|
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
|
|
Oct 9
|
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
|
|
Oct 7
|
Old Drug Repurposed for Schizophrenia Could Reap Alzheimer’s Windfall
|
|
Oct 5
|
Bristol-Myers Squibb Company (BMY): A Buzzing AI Health Stock to Add to Your Portfolio
|
|
Oct 5
|
These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
|
|
Aug 30
|
Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts
|
|
Aug 30
|
Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?
|
|
Aug 29
|
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
|
Aug 29
|
Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?
|
|
Aug 29
|
Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 17% if they invested three years ago
|
|
Aug 29
|
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
|
|
Aug 28
|
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
|
|
Aug 28
|
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|
|
Aug 28
|
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
|
|
Aug 28
|
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
|
|
Aug 27
|
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
|